NAV

Anthrax immune globulin human

Identification

Summary

Anthrax immune globulin human是一种免疫剂用于治疗吗nhalational anthrax in adult and pediatric patients in combination with antibacterial agents.

Brand Names
Anthrasil
Generic Name
Anthrax immune globulin human
DrugBank Accession Number
DB09057
Background

Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and edema toxins. This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
同义词
  • Anthrax immune globulin (human)
  • Anthrax immune globulin human
  • Anthrax immunoglobulin (human)
  • Bacillus anthracis immune globulin human

Pharmacology

Indication

Anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Polyclonal anthrax immune globulin is a passive immunizing agent that neutralizes anthrax toxin by binding to Protective Antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.

Target 行动ns Organism
AProtective antigen
抗体
 Bacillus anthracis
Absorption

Peak levels were reached immediately after infusion and then declined over the duration of study (84 days). Mean activity remained above the lower limit of quantitation (5 milliunits per mL) over the entire 84-day post-dose period for the three doses studied. Cmax was found to be 83.0 mU/mL while Tmax was found to be 0.116 days.

Volume of distribution

5714.8 mL

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

24.3 days

Clearance

174.2 mL/day

的不利影响
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

最常见的不良反应Anthrasil奥林匹克广播服务公司erved in >5% of healthy volunteers in clinical trials were headache, infusion site pain and swelling, nausea, and back pain.

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abatacept The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abatacept.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Anthrax immune globulin human.
Adalimumab The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Adalimumab.
Aducanumab The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Aducanumab.
Aldesleukin The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Aldesleukin.
Alefacept The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alefacept.
Alemtuzumab The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alemtuzumab.
Alirocumab The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Alirocumab.
Altretamine The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Altretamine.
Amivantamab The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Amivantamab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Anthrasil Liquid 60 [iU]/35mL Intravenous Emergent BioSolutions Canada Inc. 2015-10-05 Not applicable US flag
Anthrasil Solution 60 unit / vial Intravenous Emergent Biosolutions Canada Inc 2018-09-26 Not applicable Canada flag

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
VKZ83S945Z
CAS number
Not Available

References

General References
  1. Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH: Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. doi: 10.1128/AAC.00458-13. Epub 2013 Aug 26. [Article]
PubChem Substance
347910401
RxNav
1722335
Drugs.com
Drugs.com Drug Page
Wikipedia
Anthrax_immune_globulin
FDA label
Download (4.37 MB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Not Available Not Yet Recruiting Not Available Anthrax 1
Not Available Not Yet Recruiting Not Available Inhaled anthrax caused by Bacillus anthracis 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Liquid Intravenous 60 [iU]/35mL
Solution Intravenous 60 unit / vial
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.Protective antigen
Kind
Protein
Organism
Bacillus anthracis
Pharmacological action
Yes
行动ns
Antibody
General Function
Metal ion binding
Specific Function
One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby f...
Gene Name
pagA
Uniprot ID
P13423
Uniprot Name
Protective antigen
Molecular Weight
85810.325 Da

Drug created at May 11, 2015 18:08 / Updated at April 28, 2023 03:25